ERBB2 and triple-negative breast carcinoma: Of note, 13.0% of the participants’ tumors were classified as triple receptor-negative breast cancer (TNBC), with the Luminal B, HER2-negative subtype being the prevalent one in our Greek cohort (35.2%).